WUN40378 | CAS#2328140-37-8

MedKoo Cat#: 555920 | Name: WUN40378

Description:

WARNING: This product is for research use only, not for human or veterinary use.

WUN40378 is compound first reported in PCT Int. Appl. (2019), WO 201909959, in which it was described as CBFβ-RUNX1 inhibitor. WUN40378 is very similar to Ro 5-3335 but with an F instead of Cl. WUN40378 is also analog of Ro 24-7429. This product has no formal name at the moment. For the convenience of communication, a temporary code name was therefore proposed according to MedKoo Chemical Nomenclature (see web page: https://www.medkoo.com/page/naming).

Chemical Structure

WUN40378

CAS#2328140-37-8

Theoretical Analysis

MedKoo Cat#: 555920

Name: WUN40378

CAS#: 2328140-37-8

Chemical Formula: C13H10FN3O

Exact Mass: 243.0808

Molecular Weight: 243.24

Elemental Analysis: C, 64.19; H, 4.14; F, 7.81; N, 17.28; O, 6.58

Price and Availability

Size	Price	Availability
1mg	USD 150.00	Ready to ship
5mg	USD 450.00	Ready to ship
10mg	USD 750.00	Ready to ship
25mg	USD 1,650.00	Ready to ship
50mg	USD 2,950.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

139339-45-0 2328140-37-8 30195-30-3

Synonym

WUN40378; WUN 40378; WUN-40378; Ro5-3335 analog; Ro 5-3335 analog; Ro 5-3335 analog; Ro 24-7429 analog; Ro 24-7429 analog; Ro24-7429 analog;

IUPAC/Chemical Name

7-fluro-1,3-dihydro-5-(1H-pyrrol-2yl)-2H-1,4-benzodiazepin-2-one

InChi Key

WRPBNGDPQRHZHC-UHFFFAOYSA-N

InChi Code

InChI=1S/C13H10FN3O/c14-8-3-4-10-9(6-8)13(11-2-1-5-15-11)16-7-12(18)17-10/h1-6,15H,7H2,(H,17,18)

SMILES Code

O=C1NC2=CC=C(F)C=C2C(C3=CC=CN3)=NC1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

to be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#YXM211227

QC Data

View QC data: current batch, Lot#YXM211227

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

WUN40378 is compound first reported in PCT Int. Appl. (2019), WO 201909959, in which it was described as CBFβ-RUNX1 inhibitor.

In vitro activity:

TBD

In vivo activity:

TBD

	Solvent	mg/mL	mM
Solubility
	DMSO	0.0	0.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 243.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

TBD

In vitro protocol:

TBD

In vivo protocol:

TBD

1: Haubrich RH, Flexner C, Lederman MM, Hirsch M, Pettinelli CP, Ginsberg R, Lietman P, Hamzeh FM, Spector SA, Richman DD. A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. The AIDS Clinical Trials Group 213 Team. J Infect Dis. 1995 Nov;172(5):1246-52. doi: 10.1093/infdis/172.5.1246. PMID: 7594660. 2: Dunne AL, Siregar H, Mills J, Crowe SM. HIV replication in chronically infected macrophages is not inhibited by the Tat inhibitors Ro-5-3335 and Ro-24-7429. J Leukoc Biol. 1994 Sep;56(3):369-73. doi: 10.1002/jlb.56.3.369. PMID: 8083610. 3: Patki AH, Lederman MM. HIV-1 Tat protein and its inhibitor Ro 24-7429 inhibit lymphocyte proliferation and induce apoptosis in peripheral blood mononuclear cells from healthy donors. Cell Immunol. 1996 Apr 10;169(1):40-6. doi: 10.1006/cimm.1996.0088. PMID: 8612292. 4: Braddock M, Cannon P, Muckenthaler M, Kingsman AJ, Kingsman SM. Inhibition of human immunodeficiency virus type 1 Tat-dependent activation of translation in Xenopus oocytes by the benzodiazepine Ro24-7429 requires trans-activation response element loop sequences. J Virol. 1994 Jan;68(1):25-33. doi: 10.1128/JVI.68.1.25-33.1994. PMID: 8254735; PMCID: PMC236260. 5: Luznik L, Kraus G, Guatelli J, Richman D, Wong-Staal F. Tat-independent replication of human immunodeficiency viruses. J Clin Invest. 1995 Jan;95(1):328-32. doi: 10.1172/JCI117660. PMID: 7814633; PMCID: PMC295435. 6: Hsu MC, Dhingra U, Earley JV, Holly M, Keith D, Nalin CM, Richou AR, Schutt AD, Tam SY, Potash MJ, et al. Inhibition of type 1 human immunodeficiency virus replication by a tat antagonist to which the virus remains sensitive after prolonged exposure in vitro. Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6395-9. doi: 10.1073/pnas.90.14.6395. PMID: 8341644; PMCID: PMC46938. 7: Biswas DK, Ahlers CM, Dezube BJ, Pardee AB. Cooperative inhibition of NF- kappa B and Tat-induced superactivation of human immunodeficiency virus type 1 long terminal repeat. Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11044-8. doi: 10.1073/pnas.90.23.11044. PMID: 8248210; PMCID: PMC47918. 8: Biswas DK, Tius MA, Zhuo J, Pardee AB. Canventol inhibits HIV-1 replication by Tat-induced Tar-independent mechanism. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jun 1;12(2):120-7. doi: 10.1097/00042560-199606010-00004. PMID: 8680882. 9: Cupelli LA, Hsu MC. The human immunodeficiency virus type 1 Tat antagonist, Ro 5-3335, predominantly inhibits transcription initiation from the viral promoter. J Virol. 1995 Apr;69(4):2640-3. doi: 10.1128/JVI.69.4.2640-2643.1995. PMID: 7884917; PMCID: PMC188946. 10: Ehret A, Westendorp MO, Herr I, Debatin KM, Heeney JL, Frank R, Krammer PH. Resistance of chimpanzee T cells to human immunodeficiency virus type 1 Tat- enhanced oxidative stress and apoptosis. J Virol. 1996 Sep;70(9):6502-7. doi: 10.1128/JVI.70.9.6502-6507.1996. PMID: 8709290; PMCID: PMC190688.